A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab.

The article focuses on a study which examined the efficacy of ixekizumab in treating patients with psoriasis vulgaris. Clinical information on psoriasis vulgaris is provided, along with a description of the medical history of the study subjects. Study authors found increased improvement in patients who received ixekizumab in terms of health-related quality of life and pruritus symptom relief.